The impact of stereotactic pallidal surgery on the dopamine D2 receptor in Parkinson disease: A positron emission tomography study

Journal of Neurosurgery

Volumn 98, Issue 1 SUPPL., 2003, Pages 57-63

  Nakajima, Takeshi ^a,b,c   Nimura, Taro ^a,b,c   Yamaguchi, Keiichiro ^a,b,c   Ando, Tadashi ^a,b,c   Itoh, Masatoshi ^a,b,c   Yoshimoto, Takashi ^a,b,c   Shirane, Reizo ^a,b,c  

^a TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TOHOKU UNIVERSITY   (Japan)

^c MIYAGI NATIONAL HOSPITAL   (Japan)

Author keywords

Dopamine D2 receptor; Pallidotomy; Parkinson disease; Positron emission tomography

Indexed keywords

CARBON 11; DOPAMINE 2 RECEPTOR; EMONAPRIDE;

ADULT; AGED; ARTICLE; BRAIN DEPTH STIMULATION; CINGULATE GYRUS; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; FEMALE; HEMISPHERE; HUMAN; MALE; PALLIDOTOMY; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; POSTOPERATIVE PERIOD; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PUTAMEN; RECEPTOR BINDING; SCORING SYSTEM; STEREOTAXIC SURGERY; THALAMUS;

EID: 0037223175     PISSN: 00223085     EISSN: None     Source Type: Journal    
DOI: 10.3171/jns.2003.98.1.0057     Document Type: Article

References (51)

1. 11C-raclopride. Mov Disord 12:33-38, 1997
2. Baron MS, Vitek JL, Bakay RA, et al: Treatment of advanced Parkinson's disease by posterior GPi pallidotomy: 1-Year results of a pilot study. Ann Neurol 40:355-366, 1996
3. 3H-spiperone binding, dopamine and HVA concentrations in Parkinson's disease and supranuclear palsy. Eur J Pharmacol 99:167-175, 1984
4. 11C-raclopride and positron emission tomography. Ann Neurol 31:184-192, 1992
5. Davis KD, Taub E, Houle S, et al: Globus pallidus stimulation activates the cortical motor system during alleviation of parkinsonian symptoms. Nat Med 3:671-674. 1997
6. Defrise M, Townsend D, Geissbuhler A: Implementation of three-dimensional image reconstruction for multi-ring positron tomographs. Phys Med Biol 35:1361-1372, 1990
7. DeLong MR: Primate models of movement disorders of basal ganglia origin. Trends Neurosci 13:281-285, 1990
8. Dogali M, Sterio D, Fazzini E, et al: Effects of posteroventral pallidotomy on Parkinson's disease. Adv Neurol 69:585-590, 1996
9. Dostrovsky JO, Levy R, Wu JP, et al: Microstimulation-induced inhibition of neuronal firing in human globus pallidus. J Neurophysiol 84:570-574, 2000
10. Fahn S, Elton RL, Members of the UPDRS Development Committee: Unified Parkinson's Disease Rating Scale, in Fahn S, Marsden CD, Goldstein M, et al (eds): Recent Developments in Parkinson's Disease. Florham Park, NJ: Macmillan Healthcare Information, 1987, Vol 2, pp 153-163
11. Fine J, Duff J, Chen R, et al: Long-term follow-up of unilateral pallidotomy in advanced Parkinson's disease. N Engl J Med 342:1708-1714, 2000
12. Fujiwara T, Watanuki S, Yamamoto S, et al: Performance evaluation of a large axial field-of-view PET scanner: SET-2400W. Ann Nucl Med 11:307-313, 1997
13. Grafton ST, Waters C, Sutton J, et al: Pallidotomy increases activity of motor association cortex in Parkinson's disease: A positron emission tomographic study. Ann Neurol 37:776-783, 1995
14. 2 receptor density remains constant in treated Parkinson's disease. Ann Neurol 19:487-492, 1986
15. 2-dopamine receptors with PET. Int J Rad Appl Instrum [A] 41:551-555, 1990
16. 2-dopamine receptor specific brain uptake of carbon-11-labeled YM-09151-2. J Nucl Med 30:515-522, 1989
17. 2 dopamine receptor-specific carbon-11-YM-09151-2 binding in the canine brain by PET: Importance of partial volume correction. J Nucl Med 32:713-718, 1991
18. Hoehn MM, Yahr MD: Parkinsonism onset, progression and mortality. Neurology 17:427-442, 1967
19. 11C-N-methylspiperone, in rats. Ann Nucl Med 13:161-167, 1999
20. Itoh M, Yamaguchi S, Meguro K, et al: Neuroreceptor PET: assessment of dopamine neurotransmission in dementia, in Ochi H, Konishi J, Yoshiharu Y, et al (eds): Brain, Heart and Tumor Imaging. Updated PET and MRI: Proceedings of the 2nd International Osaka City University Symposium on Brain, Heart, and Tumor Imaging, Osaka, Japan, 2-4 October 1994. Amsterdam: Elsevier Science, 1995, pp 101-105
21. Jenkins IH, Fernandez W, Playford ED, et al: Impaired activation of the supplementary motor area in Parkinson's disease is reversed when akinesia is treated with apomorphine. Ann Neurol 32:749-757, 1992
22. Joyce JN: Differential response of striatal dopamine and muscarinic cholinergic receptor subtypes to the loss of dopamine. III. Results in Parkinson's disease cases. Brain Res 600:156-160, 1993
23. 3 receptors in early and advanced Parkinson's disease. Neurology 54:1482-1487, 2000
24. Kishore A, Turnbull IM, Snow BJ, et al: Efficacy, stability and predictors of outcome of pallidotomy for Parkinson's disease. Six-month follow-up with additional 1-year observations. Brain 120:729-737, 1997
25. Lang AE, Lozano A, Tasker R, et al: Neuropsychological and behavioral changes and weight gain after medial pallidotomy. Ann Neurol 41:834-836, 1997
26. Lang AE, Lozano AM: Parkinson's disease. First of two parts. N Engl J Med 339:1044-1053, 1998
27. Lang AE, Lozano AM: Parkinson's disease. Second of two parts. N Engl J Med 339:1130-1143, 1998
28. Limousin P, Greene J, Pollak P, et al: Changes in cerebral activity pattern due to subthalamic nucleus or internal pallidum stimulation in Parkinson's disease. Ann Neurol 42:283-291, 1997
29. Lozano AM, Lang AE, Galvez-Jimenez N, et al: Effect of GPi pallidotomy on motor function in Parkinson's disease. Lancet 346:1383-1387, 1995
30. Olanow CW, Watts RL, Koller WC: An algorithm (decision tree) for the management of Parkinson's disease (2001): Treatment guidelines. Neurology 56 (Suppl 5):S1-S88, 2001
31. Pardo JV, Pardo PJ, Janer KW, et al: The anterior cingulate cortex mediates processing selection in the Stroop attentional conflict paradigm. Proc Natl Acad Sci USA 87:256-259, 1990
32. 2 receptors contribute to deteriorated response to L-dopa in Parkinson's disease: A [123I]-IBZM SPET study. J Neural Transm Suppl 45:113-122, 1995
33. Playford ED, Jenkins IH, Passingham RE, et al: Impaired mesial frontal and putamen activation in Parkinson's disease: A positron emission tomography study. Ann Neurol 32:151-161, 1992
34. Posner MI, Petersen SE: The attention system of the human brain. Annu Rev Neurosci 13:25-42, 1990
35. 11C] raclopride. J Neurol Sci 132:156-161, 1995
36. Riordan HJ, Flashman LA, Roberts DW, et al: Neurocognitive and psychosocial correlates of ventroposterolateral pallidotomy surgery in Parkinson's disease. Neurosurg Focus 2 (3):Article 7, 1997
37. 2 receptor elevated in the striatum of Parkinson's disease. Mov Disord 13:788-797, 1998
38. Saint-Cyr JA, Trepanier LL: Neuropsychologic assessment of patients for movement disorder surgery. Mov Disord 15:771-783, 2000
39. Samii A, Markopoulou K, Wszolek ZK, et al: PET studies of parkinsonism associated with mutation in the alpha-synuclein gene. Neurology 53:2097-2102, 1999
40. 15O PET study. Brain 120:1301-1313, 1997
41. Schwab RS, England AC Jr: Projection technique for evaluating surgery in Parkinson's disease, in Gillingham FJ, Donaldson IML (eds): Third Symposium on Parkinson's Disease, Royal College of Surgeons in Edinburgh, May 20-22, 1968. Edinburgh: E & S Livingstone, 1969, pp 152-157
42. 2 dopamine receptors in schizophrenia, Alzheimer's, Parkinson's, and Huntington's diseases. Neuropsychopharmacology 1:5-15, 1987
43. 2 receptor reveals different densities for dopamine receptor antagonist ligands. Implications for human brain positron emission tomography. Eur J Pharmacol 227:139-146, 1992
44. 4 receptors elevated in schizophrenia. Nature 365:441-445, 1993
45. Staffen W, Hondl N, Trinka E, et al: SPET investigations in extrapyramidal diseases using specific ligands. Nucl Med Commun 18:159-163, 1997
46. Tamaru F: Disturbances in higher function in Parkinson's disease. Eur Neurol 38 (Suppl 2):33-36, 1997
47. 3H] raclopride in postmortem human brains. Brain Res 765:7-12, 1997
48. 11C] raclopride displacement and PET. Neurology 46:1430-1436, 1996
49. Thaler DE, Passingham RE: The supplementary motor cortex and internally directed movement, in Crossman AR, Sambrook M (eds): Neural Mechanisms in Disorders of Movement. London: Libby, 1989, pp 175-181
50. 2 site binding in L-dopa-treated Parkinson's disease patients with and without dyskinesias. Neurology 49:717-723, 1997
51. 3 receptor gene polymorphisms with motor fluctuations in PD. Neurology 56:1757-1759, 2001